Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy."

摘要: Abstract Background Carcinoma in situ (CIS) is a poor prognostic finding urothelial carcinoma. However, its significance muscle-invasive carcinoma (MIUC) treated with neoadjuvant chemotherapy (NAC) uncertain. We assessed the effect of CIS found pretreatment transurethral resection bladder tumor (TURBT) biopsies on pathologic and clinical outcomes. Materials methods Subjects MIUC NAC before cystectomy were identified. The complete response (pCR) rates stratified by TURBT status compared. secondary analyses included response, progression-free survival (PFS), overall (OS), an exploratory post hoc analysis patients only (pTisN0) at cystectomy. Results A total 137 was noted 30.7% patients. absence associated significantly increased pCR rate (23.2% vs. 9.5%; odds ratio = 4.08; 95% CI: 1.19–13.98; P 0.025). Stage pTisN0 disease observed 19.0% did not affect PFS or OS Post revealed prolonged median (104.5 139.9 months; 0.055) 152.3 0.091) outcomes similar to those for Conclusion undergoing rates, no differences OS. Isolated frequently observed, lengthy durations Further studies aimed understanding biology are warranted.